


# Positron Emission Tomography (PET) Scanners Market is expected to reach US\$ 1,549.7 Mn by the end of 2028

*Positron Emission Tomography (PET) is a clinical imaging method that is used to diagnose disorders such as Alzheimer's disease and cancer.*

SEATTLE, WASHINGTON, UNITED STATES, December 9, 2021

/EINPresswire.com/ -- Positron

Emission Tomography (PET) is a clinical imaging method that is used to diagnose disorders such as Alzheimer's disease and cancer. The basic concept behind PET imaging is to identify a pair of gamma rays released indirectly by a radiotracer. PET can also discriminate between malignant and nonmalignant cancers.



Click Here To Get Sample Copy @ <https://www.coherentmarketinsights.com/insight/request-sample/693>

The global [positron emission tomography \(PET\) scanners market](#) is expected to be worth US\$ 1,107.6 million in 2019 and grow to US\$ 1,549.7 million by 2027.

Global Positron Emission Tomography (PET) Scanners Market: Drivers

The rising cancer incidence is expected to drive the global positron emission tomography (PET) scanners market during the forecast period. According to the American Cancer Society, around 1,762,450 new cancer cases were reported and 606,880 cancer deaths in the U.S. in 2019.

Furthermore, the provision of Medicare coverage for PET scanning is projected to propel market growth. PET/CT scanners that use the radioisotope 18F-fluorodeoxyglucose (FDG) have a high rate of success in the diagnosis of cancer. Increased coverage for PET imaging in cancers such as melanoma, lung cancer, cervical cancer, esophageal cancer, breast cancer, ovarian cancer, myeloma, lymphoma, thyroid cancer, head and neck cancer, and colorectal cancer supports the

use of these scanners.

In 2019, Full Ring PET Scanner accounted for a major share in the global positron emission tomography (PET) scanners market, representing 84.3 % of the market share, trailed by Partial Ring PET Scanner.

### Global Positron Emission Tomography (PET) Scanners Market: Restraints

Constant reimbursement cuts are expected to hamper the global positron emission tomography (PET) scanners market during the forecast period. Globally, decreasing payer reimbursement for PET and SPECT operations has resulted in a decrease in outpatient volumes, impacting patient access to cost-effective, high-quality, diagnostic and imaging services.

Furthermore, the short half-life of radiopharmaceuticals is expected to hinder the global positron emission tomography (PET) scanners market during the forecast period. The most often used radiotracer in PET imaging is fluoro-deoxy glucose (FDG), which combines fluorine-18 as the tracer. The radiotracer has a half-life of slightly less than two hours. As a result, its diagnostic imaging utility is reduced.

Request PDF Brochure Of This Report @

<https://www.coherentmarketinsights.com/insight/request-pdf/693>

### Global Positron Emission Tomography (PET) Scanners Market: Opportunities

The increasing usage of dual-modality imaging techniques or hybrid imaging is expected to provide attractive growth prospects for market players. The use of hybrid imaging, which combines PET and X-ray transmission CT scans, is rising globally due to its potential to reduce acquisition time while also providing accurate attenuation correction and fusion imaging, resulting in increased diagnostic specificity and sensitivity.

Furthermore, the development of guidelines for the manufacturing of radiopharmaceuticals is expected to aid in the global positron emission tomography (PET) scanners market during the forecast period. For instance, the International Atomic Energy Agency approved a project in February 2020 and will provide help and expertise in the manufacturing of cyclotron-based gallium-68 radioisotopes and associated radiopharmaceuticals.

The oncology segment was worth US\$ 906.1 million in 2019 and is expected to be worth US\$ 1,270.4 million by 2027, growing at a CAGR of 4.2 % during the forecast period 2020 and 2027.

### Market Trends/Key Takeaways

A recent trend in the healthcare industry indicates a shift away from monitoring and diagnosis of cardiovascular disorders and toward prevention and prediction. As a result, radionucleotide



measurable, sustainable results for our clients.

Contact:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: [sales@coherentmarketinsights.com](mailto:sales@coherentmarketinsights.com)

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/557990921>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.